HQE1 Stock Overview
Engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Cytosorbents Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.07 |
| 52 Week High | US$1.36 |
| 52 Week Low | US$0.62 |
| Beta | 0.62 |
| 1 Month Change | 7.94% |
| 3 Month Change | 25.47% |
| 1 Year Change | 19.33% |
| 3 Year Change | -67.77% |
| 5 Year Change | -79.93% |
| Change since IPO | -71.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| HQE1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 13.7% | 0.8% | 2.7% |
| 1Y | 19.3% | -0.4% | 18.1% |
Return vs Industry: HQE1 exceeded the German Medical Equipment industry which returned -1.2% over the past year.
Return vs Market: HQE1 exceeded the German Market which returned 16.5% over the past year.
Price Volatility
| HQE1 volatility | |
|---|---|
| HQE1 Average Weekly Movement | 13.7% |
| Medical Equipment Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: HQE1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HQE1's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 186 | Phil Chan | www.cytosorbents.com |
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy.
Cytosorbents Corporation Fundamentals Summary
| HQE1 fundamental statistics | |
|---|---|
| Market cap | €60.10m |
| Earnings (TTM) | -€17.84m |
| Revenue (TTM) | €36.07m |
1.9x
P/S Ratio-3.8x
P/E RatioIs HQE1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HQE1 income statement (TTM) | |
|---|---|
| Revenue | US$37.74m |
| Cost of Revenue | US$14.07m |
| Gross Profit | US$23.67m |
| Other Expenses | US$42.34m |
| Earnings | -US$18.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 62.71% |
| Net Profit Margin | -49.47% |
| Debt/Equity Ratio | 106.2% |
How did HQE1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/13 15:44 |
| End of Day Share Price | 2025/02/13 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cytosorbents Corporation is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Aschoff | Brean Capital |
| Jason Kolbert | D. Boral Capital LLC. |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |